It's sunny to grab 1 billion anti-tumor injections! National medicine, Edgyon 8 followed closely

January 21, 2021 Drug approval documents to be received information release In recent years, China's public medical institutions terminal boron zomi injection sales (units: 100 million yuan) Source: China's public medical institutions terminal competition pattern boron tezome is the world's first protein enzyme as the target of treatment target anti-tumor drugs. In recent years, sales of boron tazami injections at urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) have steadily increased, reaching new highs in 2019 and nearly 15% year-on-year in the first half of 2020 after breaking the 1 billion mark in 2018, according to
meters of intranet data.
Injection boron tyzomi manufacturers are Xi'an Yangsen, Zhengda Tianqing Pharmaceutical Group, Jiangsu Haussen Pharmaceuticals, Qilu Pharmaceuticals and other 8, of which Xi'an Yangsen market share is the largest, accounting for 47.95 percent;
note that in recent years, with the strength of domestic pharmaceutical companies, Xi'an Yangsen's market share has declined rapidly, from 64% in 2017 to 64% in 2019, and has fallen below 50% in the first half of 2020.
Source: MED2.0 China Drug Review Database Consistency Evaluation, injection boratezomi has been evaluated by 5 enterprises, among them, Zhengda Tianqing Pharmaceutical Group, Jiangsu Howson Pharmaceuticals, Qilu Pharmaceuticals, Nanjing Zhengda Tianqing Pharmaceuticals to supplement the review, Shi Pharmaceutical Group Europharma was approved in the same category as imitation 4 categories, as reviewed.
present, the consistency evaluation supplementary application of three enterprises, such as Synractic Pharmaceuticals and Suzhou Terry Pharmaceuticals, is in the review and approval (in the drug review center).
addition, Suzhou Second Leaf Pharmaceuticals, China Pharmaceuticals One Heart Pharmaceuticals, Yangzijiang Pharmaceutical Group, Yiteng Pharmaceuticals and other 8 enterprises submitted applications for listing in the review and approval (in the drug review center).